Published in Clin Cancer Res on October 01, 2008
Cultured Circulating Tumor Cells in Prostate and Other Cancers | NCT02123862
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol (2015) 5.48
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res (2011) 3.25
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol (2011) 2.76
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer (2012) 2.49
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer (2011) 2.19
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol (2014) 2.05
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol (2010) 1.83
Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc (2014) 1.80
ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics (2012) 1.74
Cancer. Circulating tumor cells. Science (2013) 1.68
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol (2011) 1.60
Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer (2015) 1.57
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51
Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. J Urol (2015) 1.51
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. Cancer Lett (2014) 1.46
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. Prostate (2014) 1.46
A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol (2012) 1.44
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Rare cell isolation and analysis in microfluidics. Lab Chip (2014) 1.42
Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology (2015) 1.42
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 1.38
A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res (2010) 1.37
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res (2013) 1.33
Circulating tumor cells: from bench to bedside. Annu Rev Med (2012) 1.29
Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol (2010) 1.29
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate (2012) 1.28
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst (2013) 1.27
Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol (2009) 1.26
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol (2016) 1.21
Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One (2013) 1.21
Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer (2013) 1.21
Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res (2012) 1.21
Label-free isolation of circulating tumor cells in microfluidic devices: Current research and perspectives. Biomicrofluidics (2013) 1.19
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med (2014) 1.18
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med (2011) 1.15
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer (2011) 1.15
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol (2009) 1.14
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One (2014) 1.14
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer (2010) 1.14
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer (2012) 1.13
Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res (2011) 1.13
Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems. Biomicrofluidics (2013) 1.12
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol (2013) 1.12
Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics (2011) 1.11
MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol (2011) 1.10
Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol (2013) 1.09
MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest (2014) 1.09
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 1.08
Microfluidic blood cell sorting: now and beyond. Small (2014) 1.07
Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One (2013) 1.06
Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology (2011) 1.06
Circulating tumor cells and DNA as liquid biopsies. Genome Med (2013) 1.06
NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods (2013) 1.05
Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med (2013) 1.05
Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol (2009) 1.05
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist (2012) 1.04
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol (2011) 5.95
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol (2005) 3.44
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res (2007) 2.50